Drug intelligence / Profile preview

JW202313

Development stage: Unknown
Lead developer: Jewim Pharmaceuticals
Modality: Small Molecules
Administration: Inhalation

Overview

**JW202313** is an investigational chemical drug formulated as an inhalation powder for maintenance treatment of chronic obstructive pulmonary disease. It is being developed by Jingwei Pharmaceutical as a high-complexity dry-powder inhalation product. Public trial records support clinical evaluation in healthy volunteers and in patients with chronic obstructive pulmonary disease, but the precise active ingredient composition and molecular target have not been publicly disclosed.

Other names: JW-202313JW202313JW 202313

Targets

CHRM3 (M3)

Beyond the preview

Go deeper on JW202313.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JW202313.

Explore the full profile